acadia pharmaceuticals
see what the ihs markit score report has to say about acadia pharmaceuticals inc .
here' s why acadia pharmaceuticals inc. is soaring today - - the motley fool
here' s why acadia pharmaceuticals inc. is soaring today @ themotleyfool # stocks $ acad
acadia pharmaceuticals and celgene corporation have both significantly underperformed the broader market this year. are they now outstanding bargains ?
acadia pharmaceuticals is named after acadia national park based on its initial ties to new england and the park’s beauty. brann also wanted a name that started with an “a. ”
acadia pharmaceuticals has become one of the most highly valued biomedical companies in san diego largely on the promise of an experimental drug for psychosis .
shareholder alert: levi & korsinsky, llp notifies investors of an investigation involving possible securities fraud violations by the board of directors of acadia pharmaceuticals inc .
new york, july 09, 2018 - - levi & korsinsky announces it has commenced an investigation of acadia pharmaceuticals inc. concerning possible violations of federal securities laws. . on april 9, 2018, acadia ...
ps. if you are not interested in acadia pharmaceuticals anymore, you can use our free platform to see my list of over 50 other stocks with a high growth potential .
hacksell was the long - time ceo of acadia pharmaceuticals who left the firm in early 2015. he exercised stock options granted between 2006 and 2011 as he stepped out of the company .
acadia pharmaceuticals’ (acad) nuplazid (pimavanserin) is commercialized in the us market for the treatment of hallucinations and delusions related to parkinson’s disease psychosis. the company believes that it has the potential to avoid many of the side effects of existing antipsychotics, none of which have been approved by the fda. acadia pharmaceuticals also believes that the drug can potentially address key medical needs in neuropsychological and psychiatric disorders in addition to parkinson’s disease psychosis .
losses were broad based as eight out of nine sectors finished the trading session in red. urltoken has initiated research reports on the following biotechnology stocks: acadia pharmaceuticals inc. (nasdaq: acad), achaogen inc. (nasdaq: akao), achillion pharmaceuticals inc. (nasdaq: achn), and acorda therapeutics inc. (nasdaq: acor) .
this increase was due to the 120% volume growth of nuplazid sales aided by the higher selling price of the drug. for 2018 and 2019, acadia pharmaceuticals is expected to report revenues of $ 261. 41 million and $ 421. 44 million, respectively. the cost of sales incurred by acadia pharmaceuticals fell marginally from $ 2. 26 million in q1 2017 to $ 2. 15 million in q1 2018 due to higher manufacturing levels .
hacksell joined the company as chief executive in 2000, while brann served as president and chief scientific officer. (brann left the company in 2006 to establish another san diego biotech, abbey pharmaceuticals, which received seed funding from acadia. )
acadia pharmaceuticals (acad) is a biopharmaceutical company engaged in developing and bringing to market innovative medicines targeted at central nervous system disorders. of the eight analysts covering acadia pharmaceuticals in july, seven have given the stock “buy” or higher recommendations, while one has given it a “hold” rating. the mean rating for the stock is 2, and its target price is $ 47. 29, implying a potential upside of 193% over the stock’s trading price of $ 16. 13 on july 2 .
acadia pharmaceuticals inc. , a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. the company offers nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with parkinson' s disease psychosis. it is also developing pimavanserin as a treatment for dementia - related psychosis and as an adjunctive treatment for schizophrenia that are in phase iii clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. acadia pharmaceuticals inc. was founded in 1993 and is headquartered in san diego, california .
today, acadia pharmaceuticals (acad) is trending higher on news of the fda’s approval of a 34 mg capsule and 10 mg tablet of nuplazid (pimavanserin) for patients with parkinson’s disease psychosis - related hallucinations and delusions. the stock was up ~ 12% in pre - market trading .
six to nine months after the fda application is submitted, acadia is scheduled to submit a marketing application for european sales .
acadia is comprised of dedicated people working together to improve the lives of patients with central nervous system (cns) disorders .
acadia ceo uli hacksell in his san diego office. / photo by k. c. alfred * u - t san diego
acadia pharmaceuticals inc. (acad), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the jmp securities life sciences conference on wednesday, june 20, 2018, at 11: 30 a. m. eastern time in new york city. acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders .
acadia pharmaceuticals inc. (acad), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the bank of america merrill lynch health care conference 2018 on tuesday, may 15, 2018, at 10: 40 a. m. pacific time in las vegas. acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders .
acadia pharmaceuticals inc. (acad), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the goldman sachs 39th annual global healthcare conference on wednesday, june 13, 2018, at 10: 40 a. m. pacific time in rancho palos verdes, california. acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders .
further down the pipeline, acadia is testing two drugs for chronic pain and glaucoma, both with the pharma company allergan as its partner .
new york, ny / accesswire / may 7, 2018 / pharmaceutical companies acadia and portola saw their shares bursting on friday. acadia moved higher on strong first quarter results of its parkinson’s disease drug nuplazid while portola soared higher after receiving fda approval for andexx, an anticoagulant - reversal antidote .
acadia plans to sell nuplazid on its own, without a pharmaceutical partner. so the company intends to hire about 135 people for its sales staff .
acadia, with a stock value of more than $ 3. 2 billion, has gained a following among investors and stock analysts who believe nuplazid will succeed. shares of acadia closed tuesday at $ 30. 17, down 6. 4 percent for the day and up 21 percent for the year .
in february 2001, at the end of a buoyant biotech market, acadia filed for an initial public offering. but the company withdrew its offering in september of that year, citing poor market conditions. acadia then succeeded with its ipo in 2004, raising $ 35 million at $ 7 per share .
it took years for acadia’s shares to recover from the loss of the schizophrenia drug, with the first sustained rally beginning in november 2012, when shares traded for less than $ 2 apiece .
i suggest investors seek some degree of margin of safety due to high institutional ownership in acad, in particular due to the strong presence of active hedge fund investors. this will allow an investor to reduce the impact of non - fundamental factors, such as volatile block trading impact on their portfolio value. however, other important factors we must never forget to assess are the fundamentals. i recommend you take a look at our latest free analysis report on acadia pharmaceuticals to see acad’s fundamentals and whether it could be considered an undervalued opportunity .
beyond that, acadia' s report shows it' s having success at moving its clinical pipeline forward. long - term shareholders have plenty of reasons to remain optimistic about this company' s future .
the company endured a major setback in june 2008, with the failure of a schizophrenia drug in mid - stage clinical testing. its shares dropped 44 percent in one day, and acadia scrapped the medication .
it underwent a dramatic makeover four years later: the business moved to san diego, adopted its present name and changed its business focus. instead of helping other companies find drugs, acadia decided to develop its own .
acadia was founded in winooski, vt. , in 1993 as receptor technologies by mark brann, a professor at the university of vermont. the company originally focused on identifying drug candidates with its technology for rapid genomics screening .
acadia' s q2 results continue to support the idea that nuplazid is off to a fast start. that' s great news for investors, and illustrates the benefits of entering a market where there is no competition in sight .
at acadia, we are passionate about improving the lives of patients with central nervous system (cns) disorders. we are building the foundation to become a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies in the cns area .
acadia pharmaceuticals inc. (acad) today announced fda approval of a new capsule dose formulation and a new tablet strength of nuplazid (pimavanserin) to help in the treatment of patients living with hallucinations and delusions associated with parkinson’s disease psychosis. the fda approval of a 34 mg nuplazid capsule formulation will provide patients with the recommended 34 mg once daily dose in a single, small capsule, reducing patient pill burden versus the current administration of two 17 mg tablets. in addition, the fda approval of a 10 mg tablet provides an optimized lower dosage strength in those patients who are concomitantly receiving strong cytochrome 3a4 inhibitors which can inhibit the metabolism of nuplazid .
uli hacksell, chief executive for acadia, said the u. s. food and drug administration has recognized the importance of nuplazid, giving it a “breakthrough therapy” designation this past summer. drugs with that categorization get expedited review by the agency .
in this article, i will take a quick look at acadia pharmaceuticals inc’s (nasdaq: acad) recent ownership structure – an unconventional investing subject, but an important one. ownership structure of a company has been found to affect share performance over time. the effect of an active institutional investor with a similar ownership as a passive pension - fund can be vastly different on a company’s corporate governance and accountability to shareholders. while this may be more interesting for long - term investors, short - term investors can also benefit by paying attention to when these institutions trade in order to take advantage of the heightened volatility. now i will analyze acad’s shareholder registry in more detail .
looking ahead, acadia will be presenting data from its phase 2 alzheimer' s disease psychosis (adp) trial at a medical conference in november. since adp represents a larger market opportunity for nupalzid than pdp, it remains a must - watch program for shareholders .
sometime in the first quarter of 2015, acadia plans to submit a marketing application for its medication nuplazid. the drug, also known by its generic name of pimavanserin, has successfully completed phase 3 testing for parkinson’s disease psychosis. it’s in phase 2 clinical trials for schizophrenia and alzheimer’s disease psychosis .
if you want to work in an environment where you can make a difference and help build things, acadia is the place to be. for people like me, this provides challenge and excitement every day. what inspires me is that what i’m doing today will actually matter to patients living with parkinson’s disease psychosis .
we hire talented people who thrive in a dynamic environment and have the experience, resilience, and flexibility to get results. our job satisfaction is rooted in knowing that the work we do can have a real impact on the lives of patients, caregivers and the healthcare community who serve them. it is this talent, dedication and shared purpose that make acadia an exciting place to work .
in keeping with our commitment to the communities in which we do business, and in compliance with state and federal law, acadia is an equal opportunity employer. our employment policies and procedures ensure that we are committed to providing equal employment opportunities in all aspects of employment without unlawful regard to race, color, religion, national origin, ancestry, sex, sexual orientation, age, veteran’s status, marital status, medical condition, and physical or mental disability, or any other characteristic protected by law. as an equal opportunity employer, we hire without consideration as to race, religion, creed, color, national origin, age, gender, sexual orientation, marital status, veteran status or disability, or any other characteristic protected by law .
next year, the 21 - year - old company expects to begin delivering on that promise .
together, these conditions represent a huge population of patients — and thus a potentially huge pharmaceutical market .
product: nuplazid, which has gone through phase 3 clinical testing for parkinson’s disease psychosis with good results. company is expected to seek marketing approval for the medication next year from u. s. food and drug administration .
scientists have found no cure for parkinson’s disease, a neurodegenerative movement disorder that affects about a million americans, or for alzheimer’s, which afflicts more than 5 million. as both diseases are linked to aging, the number of patients is expected to grow .
there are treatments for schizophrenia, which affects roughly 1 percent of the u. s. population, but they frequently don’t work .
while these diseases have very different causes, they’re often associated with delusions, hallucinations and agitation — symptoms that nuplazid is designed to counter .
clinical testing indicates that nuplazid doesn’t produce the dangerous side effects of other anti - psychotic medications. in addition, the drug promotes sleep, an important benefit in its own right .
nuplazid blocks a specific cellular receptor — a molecular target on the surface of a cell — used by the neurotransmitter serotonin. it counteracts psychosis symptoms in parkinson’s patients without interfering with other parkinson’s medications, which often act on another neurotransmitter, dopamine .
“we think pimavanserin has a good shot at improving on the atypical (anti - psychotic drugs) for the same reason it appears to do so in parkinson’s disease psychosis: efficacy with a cleaner safety profile due to more targeted activity, ” analyst charles duncan of the research firm piper jaffray wrote in a nov. 11 research report .
“this tells us they share our view of the unmet medical need in parkinson’s disease psychosis, and that they are also impressed by the clinical data we have, ” hacksell said. “so things look very good, very exciting. ”
hallucinations related to this type of psychosis can be especially disturbing, he said. “it’s very common that they see a deceased relative on the other side of the table, ” hacksell said .
and the burden of caring for the patient frequently falls on his or her spouse, who may not know how to cope with the deterioration in behavior .
“they have paranoid delusions, they are afraid their spouse is having an affair. all of this causes a lot of stress in the relationship, ” hacksell explained. “parkinson’s psychosis is the major reason why parkinson’s patients have to go to nursing homes. the caregiver can’t deal with the patient anymore. ”
“we could have gone one of two ways — build up the company for short - term revenue as a research tool company or become a drug - discovery company, ” brann said in a 2005 interview. “my passion was to be a drug - discovery company, to develop drugs, and that’s the path we went down. ”
now, with years of testing data to buttress nuplazid’s efficacy, prospects are looking up, hacksell said. assuming all goes well, the company could have fda marketing approval sometime in mid - 2015 .
meanwhile, more clinical trials are planned for nuplazid — one for schizophrenia and another for parkinson’s patients with sleep disturbances .
•neurodegenerative disorder that makes movement increasingly difficult. symptoms include tremors, slurred speech and changes to a person’s gait .
•as many as 1 million americans have the illness, according to the parkinson’s disease foundation .
pimavanserin for patients with parkinson' s disease psychosis: a randomized, placebo - controlled phase 3 trial. the lancet, 383, 533 - 540 (2014) .
new york, ny / accesswire / july 9, 2018 / u. s. equities posted solid gains on friday, ending the week on a positive note, supported by a stronger - than - expected jobs report. the dow jones industrial average ...
these biotech stocks have taken a beating this year. but are any of them ready to rebound ?
the company saw a net income of - $ 54. 29 million in q1 2018 compared to - $ 87. 84 million in q1 2017. this resulted in the company’s net income per share rising to - $ 0. 44 in q1 2018 from its net income per share of - $ 0. 72 in q1 2017 .
this represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on june 26. index (pmi) data, output in the healthcare sector is rising .
shares pop after the company reports upbeat regulatory news. here' s what shareholders need to know .
short interest is moderately high for acad with between 10 and 15% of shares outstanding currently on loan. this represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on june 26. over the last month, growth of etfs holding acad is favorable, with net inflows of $ 6. 37 billion .
new york, ny / accesswire / june 21, 2018 / u. s. markets were mixed wednesday as global trade concerns continue to be a focus. the nasdaq and s & p 500 index posted gains driven by deal making activities ...
new york, ny / accesswire / june 14, 2018 / u. s. markets fell wednesday after the federal reserve raised interest rates and hinted at more increases were coming in 2018. the dow jones industrial average ...
the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. index (pmi) data, output in the healthcare sector is rising .
founded in 1993 by brothers tom and david gardner, the motley fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services .
shares popped after the company reported better - than - expected second quarter results and issued bullish full - year guidance .
reporting blow - out earnings and sharing upbeat guidance, shares of the commercial - stage biopharma, which focuses on diseases of the central nervous system, were trading 13. 9% higher as of 1: 35 p. m. edt on wednesday .
revenue from sales of the company' s parkinson' s disease psychosis (pdp) drug nuplazid totaled $ 30. 5 million - - far ahead of the $ 19. 6 million that wall street had expected. however, it should be noted that the figure included a one - time benefit of $ 3. 6 million because the company transitioned its revenue recognition method of accounting to the sell - in method .
net loss was $ 67. 4 million, or $ 0. 55 per share - - far lower than $ 0. 71 loss that market watchers had anticipated .
management guided for full - year sales of nuplazid to land between $ 105 million and $ 115 million. the midpoint of this range is far ahead of the $ 94 million in revenue that wall street had projected .
the company held an end - of - phase - 2 meeting with the fda related to its alzheimer' s disease psychosis program. management says that the meeting went well, and that a phase 3 study will kick off in the next few months .
25 new sales reps were deployed to expand the company' s focus on the long - term care market. the company now has more than 150 total sales reps deployed in the field .
given the better - than - expected q2 results, upbeat guidance, and positive meeting with the fda, it is easy to understand why shares are rising today .
brian feroldi has no position in any stocks mentioned. the motley fool has no position in any of the stocks mentioned. the motley fool has a disclosure policy .
brian feroldi has been covering the healthcare industry for the motley fool since 2015. brian' s investing goal is to find the highest quality companies that he can find, buy them, and then to sit back and let compounding work its magic. see all of his articles here and make sure you follow him on twitter. follow @ brianferoldi
how pandora media inc. shares soared 63. 5% higher in the first half of 2018
enter up to 25 symbols separated by commas or spaces in the text box below. these symbols will be available during your session for use on applicable pages .
don' t know the stock symbol? use the symbol lookup tool. alphabetize the sort order of my symbols
sign up now to become a urltoken member and begin receiving instant notifications when key events occur that affect the stocks you follow .
please note that once you make your selection, it will apply to all future visits to nasdaq. com. if, at any time, you are interested in reverting to our default settings, please select default setting above. if you have any questions or encounter any issues in changing your default settings, please email isfeedback @ urltoken .
you have selected to change your default setting for the quote search. this will now be your default target page; unless you change your configuration again, or you delete your cookies. are you sure you want to change your settings ?
please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first - rate market news and data you' ve come to expect from us .
with an institutional ownership of 78. 83% , acad can face volatile stock price movements if institutions execute block trades on the open market, more so, when there are relatively small amounts of shares available on the market to trade however, as not all institutions are alike, such high volatility events, especially in the short - term, have been more frequently linked to active market participants like hedge funds. considering hedge funds hold a stake of 21. 16% in the company, acad shares may experience high short - term volatility as this class of institutions are frequently found to sell significantly during market - wide shocks. we should dig deeper into the company’s ownership structure to find how the rest of its ownership structure can impact its investment case .
another important group of shareholders are company insiders. insider ownership has to do more with how the company is managed and less to do with the direct impact of the magnitude of shares trading on the market. a stake of 0. 18% in the large - cap acad is relatively significant. this means there is some alignment of interest with shareholders. a higher level of insider ownership has been found to reflect the choosing of projects with higher return on investments compared to lower returning projects for the sake of expansion. i will also like to check what insiders have been doing recently with their holdings. insider buying may be a sign of upbeat future expectations, however, selling doesn’t necessarily mean the opposite as insiders may be motivated by their personal financial needs .
bill gates dropped out of college to found microsoft. he' s a prodigy who has become one of the richest men in the world. but when it comes to the stock market, he follows the advice of billionaire investor warren buffett. so what stocks is he holding today? click here to view a
cameron graduated from a double degree in finance and economics. he currently works as an analyst at a small asset management company. he has never been a fan of shorting, and has always believed that the only type of investment strategy is going long for the long term. he says the best way to get into the market is to find a mentor who has invested and to read a lot of books and articles. reach cameron by sending an email at cameron. brookes @ urltoken .
simply wall st is an award winning start - up aiming to replace human stockbrokers by providing you with high quality financial data and analysis presented in a beautiful visual way everybody can understand, at a fraction of the cost (try our free plan) .
the opinions and content on this site are those of the contributing authors and not simply wall st. apply to become a contributor here. the information should not be considered advice and it does not take into account your investment objectives, financial situation or needs. you should seek independent financial and legal advice to consider if an investment is appropriate for your personal circumstances .
the u. s. food and drug administration today approved nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with parkinson’s disease .
hallucinations or delusions can occur in as many as 50 percent of patients with parkinson’s disease at some time during the course of their illness. people who experience them see or hear things that are not there (hallucinations) and / or have false beliefs (delusions). the hallucinations and delusions experienced with parkinson’s disease are serious symptoms, and can lead to thinking and emotions that are so impaired that the people experiencing them may not relate to loved ones well or take appropriate care of themselves .
“hallucinations and delusions can be profoundly disturbing and disabling, ” said mitchell mathis, m. d. , director of the division of psychiatry products in the fda’s center for drug evaluation and research. “nuplazid represents an important treatment for people with parkinson’s disease who experience these symptoms. ”
an estimated 50, 000 americans are diagnosed with parkinson’s disease each year, according to the national institutes of health, and about one million americans have the condition. the neurological disorder typically occurs in people over age 60, when cells in the brain that produce a chemical called dopamine become impaired or die. dopamine helps transmit signals between the areas of the brain that produce smooth, purposeful movement - - like eating, writing and shaving. early symptoms of the disease are subtle and occur gradually. in some people parkinson’s disease progresses more quickly than in others. as the disease progresses, the shaking, or tremor, which affects the majority of people with parkinson’s disease, may begin to interfere with daily activities. other symptoms may include depression and other emotional changes; hallucinations and delusions; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions .
the effectiveness of nuplazid was shown in a six - week clinical trial of 199 participants. nuplazid was shown to be superior to placebo in decreasing the frequency and / or severity of hallucinations and delusions without worsening the primary motor symptoms of parkinson’s disease .
as with other atypical antipsychotic drugs, nuplazid has a boxed warning alerting health care professionals about an increased risk of death associated with the use of these drugs to treat older people with dementia - related psychosis. no drug in this class is approved to treat patients with dementia - related psychosis .
in clinical trials, the most common side effects reported by participants taking nuplazid were: swelling, usually of the ankles, legs, and feet due to the accumulation of excessive fluid in the tissue (peripheral edema); nausea; and abnormal state of mind (confused state) .
nuplazid was granted breakthrough therapy designation for the treatment of hallucinations and delusions associated with parkinson’s disease. breakthrough therapy designation is a program designed to expedite the development and review of drugs that are intended to treat a serious condition and where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint. the drug was also granted a priority review. the fda’s priority review program provides for an expedited review of drugs that offer a significant improvement in the safety or effectiveness for the treatment, prevention, or diagnosis of a serious condition .
the fda, an agency within the u. s. department of health and human services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. the agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products .
page last updated: 05 / 02 / 2016 note: if you need help accessing information in different file formats, see instructions for downloading viewers and players. language assistance available: español | 繁體中文 | tiếng việt | 한국어 | tagalog | русский | العربية | kreyòl ayisyen | français | polski | português | italiano | deutsch | 日本語 | فارسی | english
and compensation values are for the last fiscal year ending on that date. pay is salary, bonuses, etc. exercised is the value of options exercised during the fiscal year. currency in usd .
the pillar scores are audit: 2; board: 4; shareholder rights: 8; compensation: 10 .
scores indicate decile rank relative to index or region. a decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
acadia pharmaceuticals , inc. is a biopharmaceutical company . the company has a portfolio of four product candidates , including pimavanserin , which is in phase iv development as a treatment for parkinson 's disease psychosis . it is also developing agn xx/yy , a product candidate in phase ii for chronic pain ; and ac-262271 , a product candidate in phase i for glaucoma , both in collaboration with allergan , as well as am-831 , a product candidate in ind-track development for schizophrenia in collaboration with meiji seika kaisha . the product candidates in the company 's pipeline emanate from discoveries made using its proprietary drug discovery platform . 
acadia pharmaceuticals, inc. is a biopharmaceutical company. the company has a portfolio of four product candidates, including pimavanserin, which is in phase iv development as a treatment for parkinson's disease psychosis. it is also developing agn xx/yy, a product candidate in phase ii for chronic pain; and ac-262271, a product candidate in phase i for glaucoma, both in collaboration with allergan, as well as am-831, a product candidate in ind-track development for schizophrenia in collaboration with meiji seika kaisha. the product candidates in the company's pipeline emanate from discoveries made using its proprietary drug discovery platform.
acadia pharmaceuticals, inc. is a biopharmaceutical company. the company has a portfolio of four product candidates, including pimavanserin, which is in phase iv development as a treatment for parkinson's disease psychosis. it is also developing agn xx/yy, a product candidate in phase ii for chronic pain; and ac-262271, a product candidate in phase i for glaucoma, both in collaboration with allergan, as well as am-831, a product candidate in ind-track development for schizophrenia in collaboration with meiji seika kaisha. the product candidates in the company's pipeline emanate from discoveries made using its proprietary drug discovery platform.